Please try another search
ENDRA Life Sciences Inc. develops technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the diagnosis and treatment of various medical conditions in circumstances where other diagnostic technologies are unavailable or impractical. The Company has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and staging the progression of non-alcoholic fatty liver disease (NAFLD), which, if untreated, can progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The Company's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
Name | Age | Since | Title |
---|---|---|---|
Francois Michelon | 55 | 2015 | Chairman, President & CEO |
Alexander Y. Tokman | 60 | 2008 | Independent Director |
Anthony DiGiandomenico | 55 | 2013 | Independent Director |
Jing Gao | - | - | Scientific Advisor |
Michael John Harsh | 68 | 2015 | Independent Director |
Jonathan Rubin | - | 2015 | Scientific Advisor |
Louis J. Basenese | 44 | 2020 | Independent Director |
Raza Malik | - | 2020 | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review